Investigating how YAP/TAZ proteins affect kidney cancer
Official title: The Oncogenic functions of YAP/TAZ in Renal Cell Carcinoma
Funded at Georgetown University · NIH-11061291 · Data updated 2026-11-12
This study is looking at how certain proteins called YAP and TAZ affect kidney cancer and hopes to find out if blocking them can change how cancer cells behave, which could help develop new treatments for people with kidney cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | April 7, 2022 |
| Project end | April 6, 2027 |
| Funding year | 2025 |
| Award (this year) | $54,538 |
| NIH project number | 5F30CA264884-04 |
| Project ID | NIH-11061291 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with renal cell carcinoma, particularly those with advanced or metastatic disease.
✕Less likely to help
Patients with early-stage renal cell carcinoma or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on renal cell carcinoma (RCC), a common and deadly form of kidney cancer. The study aims to understand the role of YAP/TAZ proteins in cancer progression by examining how their inhibition can alter cancer cell behavior. Using advanced techniques, researchers will analyze patient-derived cells to see how blocking these proteins affects cancer-related gene activity and the overall cancer environment. This could lead to new treatment strategies for patients with RCC.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients suffering from renal cell carcinoma.
How similar studies have gone: Other research has shown promising results in targeting similar oncogenic pathways, suggesting that this approach could be effective.
Where this research is happening
-
Georgetown University
Washington, United States Active
Researchers
- Principal investigator: Mcintosh, Alec Thomas — Georgetown University
- Study coordinator: Mcintosh, Alec Thomas
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.